Simcere Pharmaceutical Group (ADR)  

(Public, NYSE:SCR)   Watch this stock  
Find more results for NYSE: SCR
- Close
NYSE real-time data - Disclaimer
Currency in
Range     -
52 week     -
Open     -
Vol. 0.00
Mkt cap 539.00M
P/E 0.00
Div/yield     -
EPS 0.17
Shares     -
Beta 0.36
Inst. own     -

Key stats and ratios

Q2 (Jun '13) 2012
Net profit margin 0.62% -0.69%
Operating margin 2.22% 1.90%
EBITD margin - 11.54%
Return on average assets 0.33% -0.41%
Return on average equity 1.60% 2.80%
Employees 4,349 -
CDP Score - -


No.699-18 Xuan Wu Avenue Xuan Wu District
+86-25-85566666 (Phone)
+86-25-85477666 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Simcere Pharmaceutical Group (Simcere) is a holding company. The Company principally engaged in the research, development, manufacture and distribution of pharmaceutical and vaccine products in the People’s Republic of China. Company markets and sells its products directly or indirectly to approximately 1,405 pharmaceutical distributors who in turn sell these products to other distributors, hospitals and retail pharmacies throughout China. As of March 31, 2013, the Company also had over 11 product candidates in various stages of development, including treatments for cancer and cardiovascular diseases. In December 2013, Simcere completed the merger contemplated by the previously announced Agreement and Plan of Merger among the Company, Simcere Holding Limited (Parent) and Simcere Acquisition Limited (Merger Sub), and as a result of the merger, the Company became a wholly owned subsidiary of Parent.